Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | 12.8x - 14.2x | 13.5x |
| Selected Fwd P/E Multiple | 6.6x - 7.3x | 7.0x |
| Fair Value | kr34.84 - kr38.51 | kr36.68 |
| Upside | 23.3% - 36.3% | 29.8% |
| Benchmarks | - | Full Ticker |
| Novo Nordisk A/S | - | CPSE:NOVOB |
| Novartis AG | - | SWX:NOVN |
| Orion Oyj | - | HLSE:ORNAV |
| Sanofi | - | ENXTPA:SAN |
| AstraZeneca PLC | - | OM:AZN |
| H. Lundbeck A/S | - | CPSE:HLUNA |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| NOVO B | NOVN | ORNAV | SAN | AZN | HLUN A | |||
| CPSE:NOVOB | SWX:NOVN | HLSE:ORNAV | ENXTPA:SAN | OM:AZN | CPSE:HLUNA | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 21.0% | 10.8% | 10.5% | 14.0% | 39.4% | 6.3% | ||
| 3Y CAGR | 28.4% | -19.5% | 19.4% | -4.1% | 297.5% | 33.6% | ||
| Latest Twelve Months | 20.7% | 41.2% | 60.2% | 37.0% | 22.8% | 37.2% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 33.7% | 26.9% | 20.7% | 18.3% | 9.2% | 10.4% | ||
| Prior Fiscal Year | 36.0% | 18.4% | 18.2% | 12.3% | 13.0% | 11.5% | ||
| Latest Fiscal Year | 34.8% | 23.1% | 21.4% | 12.4% | 13.0% | 14.3% | ||
| Latest Twelve Months | 34.8% | 24.2% | 21.9% | 13.8% | 14.1% | 14.3% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 14.3x | 11.2x | 18.0x | 10.7x | 13.5x | 7.0x | ||
| Price / LTM Sales | 7.0x | 4.2x | 5.0x | 2.6x | 4.0x | 1.4x | ||
| LTM P/E Ratio | 20.0x | 17.4x | 22.7x | 19.2x | 28.5x | 9.9x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | 17.4x | 20.0x | 28.5x | |||||
| Historical LTM P/E Ratio | 9.9x | 15.9x | 45.9x | |||||
| Selected P/E Multiple | 12.8x | 13.5x | 14.2x | |||||
| (x) LTM Net Income | 3,143 | 3,143 | 3,143 | |||||
| (=) Equity Value | 40,367 | 42,491 | 44,616 | |||||
| (/) Shares Outstanding | 1,128.7 | 1,128.7 | 1,128.7 | |||||
| Implied Value Range | 35.76 | 37.65 | 39.53 | |||||
| FX Rate: DKK/DKK | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 35.76 | 37.65 | 39.53 | 28.25 | ||||
| Upside / (Downside) | 26.6% | 33.3% | 39.9% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | NOVO B | NOVN | ORNAV | SAN | AZN | HLUN A | |
| Value of Common Equity | 2,023,764 | 223,329 | 7,899 | 119,122 | 221,439 | 31,886 | |
| (/) Shares Outstanding | 4,439.1 | 1,959.3 | 140.7 | 1,216.5 | 1,550.6 | 1,128.7 | |
| Implied Stock Price | 455.90 | 113.99 | 56.14 | 97.92 | 142.80 | 28.25 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.21 | 1.00 | 1.00 | 0.10 | 1.00 | |
| Implied Stock Price (Trading Cur) | 455.90 | 94.21 | 56.14 | 97.92 | 1,379.00 | 28.25 | |
| Trading Currency | DKK | CHF | EUR | EUR | SEK | DKK | |
| FX Rate to Reporting Currency | 1.00 | 1.21 | 1.00 | 1.00 | 0.10 | 1.00 | |